Update on Hormone Receptor-Positive MBC - Metastatic Breast Cancer Trial Talk

Research News

Hormone receptor-positive (HR-positive) metastatic breast cancer is an MBC subtype that tests positive for estrogen receptors, progesterone receptors, or both. HR-positive MBC can be either positive or negative for the HER2 receptor.

While HR-positive MBC is typically sensitive to hormone therapy, it often develops treatment resistance to hormone therapy. See below to read research on newer hormone therapies, targeted therapies like CDK4/6 inhibitors, mTOR inhibitors, PI3K inhibitors, and other therapy combinations for HR-positive MBC. 

Videos
Articles
Clinical Trials for Hormone Receptor-Positive MBC

Last Modified on April 5, 2021

Tags:

SEARCH OUR SITE

for past articles or specific information.